- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 72
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tumor Necrosis Factor Inhibitors, Abatacept
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63,013 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infection
- Interventions
- IL-2 plus Anti-TNF or Thalidomide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Spondyloarthritis
- Interventions
- Ixekizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Interventions
- Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
- Drug
- Lead sponsor
- Jeffrey Curtis
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
- Conditions
- Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriatic Nail
- Interventions
- Etanercept, OCT
- Drug · Device
- Lead sponsor
- OptiSkin Medical
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pregnancy
- Interventions
- Etanercept
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Crohn's Disease
- Interventions
- Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 88
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Clazakizumab, Placebo (Matching with Clazakizumab)
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Hot Springs, Arkansas • Long Beach, California + 16 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Peoria, Arizona • La Jolla, California • Los Angeles, California + 13 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tofacitinib, TNF Inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
- Drug
- Lead sponsor
- Dr. Larry W. Moreland
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- No intervention
- Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 23,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 107
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more
- Conditions
- Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
- Interventions
- Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Edentulism, Dental Implants, TNF-alpha Inhibitors
- Interventions
- Placement of dental implants
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo
- Drug
- Lead sponsor
- Abivax S.A.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- San Diego, California • Decatur, Georgia • Austin, Texas + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 74
- States / cities
- Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more
- Conditions
- Rheumatoid Arthritis, Cardiovascular Disease
- Interventions
- Certolizumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ulcerative Colitis
- Interventions
- Vedolizumab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- PF-05280586, MabThera, Rituxan
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 32 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 487 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 85
- States / cities
- Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more